Trade Immunocore Holdings plc - IMCR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company''s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Latest shares articles

Nvidia results preview: what to expect from Q3 after the AI sell-off
Revenue guidance of USD 108bn, a new interim CEO and an AI sell-off: what investors are watching as Nvidia reports its fiscal Q3 2027 results.
12:06, 17 November 2026

What you need to know about Alphabet after the biggest one-day drop in its history – break-down
Google Cloud is growing fast, but AI spending pushed Alphabet’s free cash flow negative. A full break-down of results, valuation, debt and risks for GOOGL
11:53, 13 November 2026

Amazon's USD 220bn bet: how record AI spending could reshape the company
Amazon plans about USD 220bn of capex in 2026. We look at AWS, profitability, debt, valuation and the key catalysts and risks for AMZN shares.
10:50, 6 November 2026

US midterms: the end of uncertainty could give Wall Street direction
Markets dislike uncertainty and volatility tends to rise ahead of the vote, but once the results are known, indices may be able to set a clearer direction.
13:28, 29 October 2026
Related News